文献速递类风湿关节炎

依那西普治疗的类风湿关节炎患者蛋白质组学研究识别出与临床结局指标相关的推定生物标志物

A proteomics study of rheumatoid arthritis patients on etanercept identifies putative biomarkers associated with clinical outcome measures.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该研究采用SWATH-MS质谱技术分析180例类风湿关节炎患者依那西普治疗前及治疗3个月后的血清蛋白质组,回归分析蛋白质水平与DAS28及其亚组分和DAS28<2.6缓解的关联,并在58例独立验证集中重复验证。发现10个蛋白质与临床结局指标显著相关,其中T复合蛋白1亚基η与DAS28缓解的关联在独立队列中重复验证,亚网络分析显示急性期和急性炎症反应主题关联最强。

要点

  • 180例RA患者依那西普治疗前血清中10个蛋白质与DAS28及其亚组分和缓解显著相关。
  • T复合蛋白1亚基η与DAS28缓解的关联在58例独立验证队列中重复验证。
  • 亚网络分析显示10个蛋白质最强关联主题为急性期和急性炎症反应。

核心结论

  • 这项纳入180例开始依那西普治疗的RA患者的纵向研究识别出若干该药治疗反应的推定蛋白质生物标志物,其中一个在独立队列中重复验证。

研究设计与样本

  • 采用SWATH-MS质谱技术生成RA患者依那西普治疗前及治疗3个月后的血清谱图,蛋白质水平与DAS28及其亚组分和DAS28<2.6缓解进行回归分析,最强关联蛋白质在独立重复验证集中分析,并使用Disease Module Detection算法进行亚网络分析、通过富集分析评估生物学合理性。
  • 发现数据集纳入180例RA患者,验证数据集纳入58例,来自一项基于英国的前瞻性多中心研究。

主要发现

  • 发现10个单个蛋白质与RA临床结局指标显著相关。
  • T复合蛋白1亚基η与DAS28缓解的关联在独立队列中重复验证。
  • 对回归分析中10个蛋白质的亚网络分析识别出本体论主题,最强关联为急性期和急性炎症反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Biologic DMARDs (bDMARDs) are widely used in patients with RA, but response to bDMARDs is heterogeneous. The objective of this work was to identify pretreatment proteomic biomarkers associated with RA clinical outcome measures in patients starting bDMARDs. METHODS: Sequential window acquisition of all theoretical fragment ion spectra mass spectrometry (SWATH-MS) was used to generate spectral maps of sera from patients with RA before and after 3 months of treatment with the bDMARD etanercept. Protein levels were regressed against RA clinical outcome measures, i.e. 28-joint DAS (DAS28) and its subcomponents and DAS28 <2.6 (i.e. remission). The proteins with the strongest evidence for association were analysed in an independent, replication dataset. Finally, subnetwork analysis was carried out using the Disease Module Detection algorithm and biological plausibility of identified proteins was assessed by enrichment analysis. RESULTS: A total of 180 patients with RA were included in the discovery dataset and 58 in the validation dataset from a UK-based prospective multicentre study. Ten individual proteins were found to be significantly associated with RA clinical outcome measures. The association of T-complex protein 1 subunit η with DAS28 remission was replicated in an independent cohort. Subnetwork analysis of the 10 proteins from the regression analysis identified the ontological theme, with the strongest associations being with acute phase and acute inflammatory responses. CONCLUSION: This longitudinal study of 180 patients with RA commencing etanercept has identified several putative protein biomarkers of treatment response to this drug, one of which was replicated in an independent cohort.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Ling SF, Yap CF, Nair N, et al. A proteomics study of rheumatoid arthritis patients on etanercept identifies putative biomarkers associated with clinical outcome measures. Rheumatology (Oxford). 2024. PMID: 37389432. doi:10.1093/rheumatology/kead321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。